Evaluation of antifungal susceptibility and clinical characteristics in fungal keratitis in a tertiary care center in North India

被引:3
作者
Vanathi, Murugesan [1 ]
Naik, Ravinder [1 ]
Sidhu, Navneet [1 ]
Ahmed, Nishat Hussain [2 ]
Gupta, Noopur [1 ]
Tandon, Radhika [1 ]
机构
[1] All India Inst Med Sci, Dr R P Ctr Ophthalm Sci, Cornea Lens & Refract Surg Serv, New Delhi, India
[2] All India Inst Med Sci, Dr R P Ctr Ophthalm Sci, Ocular Microbiol Serv, New Delhi, India
关键词
Amphotericin B; antifungal susceptibility testing; fungal keratitis; natamycin; posaconazole; IN-VITRO SUSCEPTIBILITY; MOLECULAR CHARACTERIZATION; FUSARIUM KERATITIS; FILAMENTOUS FUNGI; AMPHOTERICIN-B; SOUTH-INDIA; ASPERGILLUS; VORICONAZOLE; RESISTANCE; AGENTS;
D O I
10.4103/ijo.IJO_855_22
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To study the antifungal susceptibility of common corneal pathogenic fungi to antifungal agents in the North Indian population. Methods: Prospective study of the antifungal sensitivity testing (natamycin, amphotericin B, voriconazole, itraconazole, fluconazole, posaconazole, caspofungin, micafungin) of fungal isolates from 50 cases of culture positive fungal keratitis by using E test method. Details noted included demographic data, visual acuity, clinical details, grade of keratitis, healing time, and success in medical management. Results: Of 50 patients with fungal keratitis (mean age: 40.28 +/- 16.77 years), 12 eyes healed within 3 weeks, 14 had a delayed healing response, and 24 had chronic keratitis. Among the 15 cases of Fusarium isolates, 93.3% were sensitive to natamycin, while 40% to amphotericin B; 66.6% to voriconazole, 13.4% to itraconazole and fluconazole each. 80% of Fusarium cases (n = 12) showed susceptibility to posaconazole. Among Aspergillus flavus isolates, 53.4% (n = 8) were sensitive to natamycin, with only 40% (n = 7) showing sensitivity to amphotericin B and good susceptibility to azoles. MIC against susceptible Fusarium spp. for natamycin was 3-16 mu g/mL, amphotericin B: 1-8 mu g/mL, voriconazole: 0.5-1.5 mu g/mL, itraconazole: 0.5-12 mu g/mL, posaconazole: 0.094-1.5 mu g/mL. MIC against Aspergillus flavus was natamycin: 8-32 mu g/mL, amphotericin B: 0.5-16 mu g/mL, voriconazole: 0.025-4 mu g/mL, itraconazole: 0.125-8 mu g/mL, posaconazole: 0.047-0.25 mu g/mL; against Aspergillus niger isolates, to natamycin was 6 mu g/mL (n=1), amphotericin B 8-12 mu g/mL (n = 3), voriconazole: 0.125-0.19 mu g/mL (n = 3), itraconazole: 0.38-0.75 mu g/mL, posaconazole: 0.064-0.19 mu g/mL and against Aspergillus fumigatus (n = 1), was natamycin4 mu g/mL, amphotericin B - 8 mu g/mL, voriconazole 0.25 mu g/mL, itraconazole 1 mu g/mL, and posaconazole 0.19 mu g/mL. MIC against susceptible Acremonium spp. for natamycin was 1.5-16 mu g/mL, amphotericin B: 0.5-8 mu g/mL, voriconazole: 0.19-3 mu g/mL, itraconazole: 0.125 mu g/mL, posaconazole: 0.125-0.5 mu g/mL and against susceptible Curvularia was natamycin 0.75-4 mu g/mL, amphotericin B 0.5-1 mu g/mL, voriconazole 0.125-0.19 mu g/mL, itraconazole 0.047-0.094 mu g/mL, posaconazole 0.047-0.094 mu g/mL. MIC against Mucor spp.+ Rhizopus spp. (n = 1) was natamycin: 8 mu g/mL, amphotericin B: 0.75 mu g/mL, posaconazole: 1.5 mu g/mL. MIC against of Alternaria (n = 1) was voriconazole: 0.19 mu g/mL, posaconazole: 0.094 mu g/mL. MIC against Penicillium (n=1) was natamycin: 8 mu g/mL, voriconazole: 0.25 mu g/mL, itraconazole: 0.5 mu g/mL, and Posaconazole: 0.125 mu g/mL. Conclusion: Our observations highlight the variations in susceptibility to antifungal agents. Posaconazole seems to be effective with low MIC against common corneal pathogenic fungal isolates.
引用
收藏
页码:4270 / 4283
页数:14
相关论文
共 56 条
  • [1] Successful Salvage Treatment of Scedosporium apiospermum Keratitis with Topical Voriconazole After Failure of Natamycin
    Al-Badriyeh, Daoud
    Leung, Lok
    Davies, Geoffrey E.
    Stewart, Kay
    Kong, David
    [J]. ANNALS OF PHARMACOTHERAPY, 2009, 43 (06) : 1139 - 1142
  • [2] Echinocandin resistance: an emerging clinical problem?
    Arendrup, Maiken C.
    Perlin, David S.
    [J]. CURRENT OPINION IN INFECTIOUS DISEASES, 2014, 27 (06) : 484 - 492
  • [3] Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus
    Arikan, Sevtap
    Sancak, Banu
    Alp, Sehnaz
    Hascelik, Gulsen
    Mcnicholas, Paul
    [J]. MEDICAL MYCOLOGY, 2008, 46 (06) : 567 - 573
  • [4] Current status of antifungal susceptibility testing methods
    Arikan, Sevtap
    [J]. MEDICAL MYCOLOGY, 2007, 45 (07) : 569 - 587
  • [5] Bansal Yashik, 2019, Curr Med Mycol, V5, P43, DOI 10.18502/cmm.5.4.2149
  • [6] Spectrum of fungal keratitis in North India
    Chowdhary, A
    Singh, K
    [J]. CORNEA, 2005, 24 (01) : 8 - 15
  • [7] Medical interventions for fungal keratitis
    FlorCruz, Nilo Vincent
    Peczon, Ildefonso V.
    Evans, Jennifer R.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (02):
  • [8] Microscopic Evaluation, Molecular Identification, Antifungal Susceptibility, and Clinical Outcomes in Fusarium, Aspergillus and, Dematiaceous Keratitis
    Gajjar, Devarshi U.
    Pal, Anuradha K.
    Ghodadra, Bharat K.
    Vasavada, Abhay R.
    [J]. BIOMED RESEARCH INTERNATIONAL, 2013, 2013
  • [9] Fungal keratitis in London - Microbiological and clinical evaluation
    Galarreta, David J.
    Tuft, Stephen J.
    Ramsay, Andrew
    Dart, John K. G.
    [J]. CORNEA, 2007, 26 (09) : 1082 - 1086
  • [10] Antifungal agents: Mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance
    Ghannoum, MA
    Rice, LB
    [J]. CLINICAL MICROBIOLOGY REVIEWS, 1999, 12 (04) : 501 - +